Balixafortide

• UNSPSC Description:

  Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s [1][2].

• Target Antigen:

  Arrestin; CXCR

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/balixafortide.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N(CCC1)[C@]1([H])C(N[C@H](C(N[C@H](C(N[C@H]2C)=O)CC3=CN=CN3)=O)CC(C=C4)=CC=C4O)=O)[C@](CCC5)([H])N5C([C@@H](NC([C@@H](NC([C@@H](NC([C@@](CSSC[C@](C(N[C@H](C(N[C@H](C(N6[C@]7([H])CCC6)=O)C)=O)CO)=O)([H])NC2=O)([H])NC([C@@H](NC([C@@H](NC([C@@H](NC7=O)CCN)=O)CCCNC(N)=N)=O)CC(C=C8)=CC=C8O)=O)=O)CC(C=C9)=CC=C9O)=O)CCC(N)=O)=O)CCCCN)=O

• Molecular Weight:

  1864.11

• References & Citations:

  [1]Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103.|[2]Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  1051366-32-5